High-Dose Vitamin C and Advanced Cancer:
Revisiting the Early Clinical Study by Cameron and Campbell
Research into high-dose vitamin C in cancer medicine is not a recent development. As early as 1974,
Cameron and Campbell published a clinical study involving patients with advanced cancer, which later
became one of the important early papers in this field.
Research into high-dose vitamin C in cancer medicine is not a recent development. As early as 1974, Cameron and Campbell published a clinical study in Chemico-Biological Interactions involving patients with advanced cancer, exploring the potential role of high-dose ascorbic acid in people living with cancer. The study subsequently became one of the important early publications in the development of research on high-dose vitamin C and cancer.
What Did the Study Investigate?
The study included 50 patients with advanced cancer. Patients received high-dose ascorbic acid using a combination of intravenous administration followed by oral supplementation.
The researchers mainly observed clinical changes after high-dose vitamin C administration, including overall physical condition, symptoms, and tumour-related findings.
Participants
50 Patients
Patients with advanced cancer
Administration
IV + Oral
High-dose ascorbic acid supplementation
Observation
Clinical Changes
Physical condition, symptoms and tumour-related findings
The report described varying degrees of clinical improvement in some patients, while tumour regression was also reported in individual cases. However, responses varied considerably between patients, and not all participants experienced noticeable changes.
Why Did This Study Attract Attention?
One reason the study attracted attention was that it raised an early clinical question: whether high-dose ascorbic acid might produce biological effects in patients with cancer that differ from those associated with ordinary nutritional supplementation.
Intravenous and oral vitamin C are not identical research questions
Later research found that intravenous and oral vitamin C can produce markedly different blood concentrations.
Intravenous administration bypasses limitations associated with intestinal absorption, allowing plasma ascorbate concentrations to reach levels far above those generally achievable through oral supplementation.
This difference contributed to renewed scientific interest in high-dose intravenous vitamin C as a research area distinct from ordinary vitamin supplementation.
How Should the Results Be Interpreted?
Although Cameron and Campbell reported several clinically interesting observations, the study has important limitations when assessed according to modern evidence-based medicine standards.
No Randomisation
Patients were not randomly assigned to different groups, meaning that underlying differences in cancer type, disease severity and prognosis may have influenced the observations.
No Concurrent Placebo Control
There was no comparable group receiving similar medical care without high-dose vitamin C, making it difficult to determine the true cause of any observed clinical change.
Different Cancer Types
The study included patients with different types of cancer and varying disease conditions.
Limited Generalisability
Because of the study design and differences among participants, the findings cannot be directly applied to all patients with cancer.
How Does Modern Medicine View High-Dose Vitamin C?
Since then, high-dose vitamin C has continued to be studied in laboratory, animal and human clinical research.
One of the better-established findings is that intravenous vitamin C can achieve substantially higher blood concentrations than oral administration. Laboratory research has also observed that high concentrations of ascorbate may influence the redox environment and cellular behaviour of certain cancer cells.
Laboratory findings are not the same as proven clinical benefit
A biological effect observed in laboratory studies does not mean that a clinical benefit has already been demonstrated in patients.
More high-quality, cancer-specific clinical studies are still needed to determine the actual clinical significance of high-dose intravenous vitamin C for different groups of patients.
The NCI continues to describe this as an area of ongoing research rather than an approach that can replace established standard cancer care.
How Does BMS Clinic Approach This Topic?
For patients with cancer, high-dose intravenous vitamin C should not simply be regarded as ordinary vitamin supplementation, nor should it be viewed as a replacement for standard cancer care.
Before considering this form of medical support, several aspects of the patient’s current health and medical situation should be assessed:
✓ Current cancer status
✓ Current medical treatment plan
✓ Kidney function
✓ G6PD status
✓ Current medications
✓ Other individual risk factors
BMS Clinic places emphasis on assessment based on medical evidence and each individual’s health condition. Where appropriate, nutritional and medical support should be considered together with the patient’s existing care plan, rather than viewing a single study or intervention in isolation.
The information on this page is provided for medical education and literature reference purposes only and is not intended to replace the assessment or advice of a doctor, registered healthcare professional or other qualified medical professional.
The study published by Cameron and Campbell in 1974 was an early clinical investigation with important methodological limitations. Its findings alone do not establish that high-dose Vitamin C can control cancer or improve clinical outcomes.
Cancer patients considering high-dose intravenous Vitamin C or other forms of supportive care should undergo an individualized assessment by a qualified healthcare professional based on their medical condition, current medical management and relevant risk factors.
Learn More About High-Dose Vitamin C Medical Support
If you would like to learn more about high-dose intravenous Vitamin C, related medical assessment and individualized health support, please contact the BMS Clinic professional team for further information.
Book a Professional Consultation Understanding High-Dose Vitamin CReferences
Cameron E, Campbell A. The orthomolecular treatment of cancer. II. Clinical trial of high-dose ascorbic acid supplements in advanced human cancer. Chem Biol Interact. 1974;9(4):285–315.
Creagan ET, Moertel CG, O'Fallon JR, et al. Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med. 1979;301(13):687–690.
Moertel CG, Fleming TR, Creagan ET, et al. High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med. 1985;312(3):137–141.
National Cancer Institute. Intravenous Vitamin C (PDQ®)–Health Professional Version. National Cancer Institute.
van Gorkom GNY, Lookermans EL, Van Elssen CHMJ, Bos GMJ. The Effect of Vitamin C (Ascorbic Acid) in the Treatment of Patients with Cancer: A Systematic Review. Nutrients. 2019;11(5):977.